United States

Genomic Health Inc (GHDX.O)

GHDX.O on Nasdaq

28 Apr 2017
Change (% chg)

$0.08 (+0.24%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Genomic Health says may sell up to 13.7 mln shares
Thursday, 11 Aug 2016 05:34pm EDT 

Genomic Health Inc : Says may sell up to an aggregate of 13.7 million shares of common stock - SEC filing .Shares being offered by selling stockholders, co will not receive any proceeds from the sale.  Full Article

Genomic Health files for mixed shelf of up to $350 mln - SEC filing
Thursday, 11 Aug 2016 04:15pm EDT 

Genomic Health Inc : Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2b0l97v ) Further company coverage: [GHDX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Genomic Health posts Q2 loss per share $0.18
Tuesday, 2 Aug 2016 04:05pm EDT 

Genomic Health Inc : Q2 loss per share $0.18 . Q2 revenue $82 million versus $70.6 million . Is raising low end of both revenue and test guidance for full-year ending December 31, 2016 . Maintaining net loss guidance between $12 and $18 million at mid-point of revenue guidance, excluding items for 2016 . FY2016 earnings per share view $-0.45, revenue view $330.3 million -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.18, revenue view $81.3 million -- Thomson Reuters I/B/E/S . Raising total revenue to between $325 and $335 million for 2016 .Sees 2016 basic net loss per share of between $0.37 and $0.55.  Full Article

Genomic Health Inc raises FY 2015 guidance
Tuesday, 4 Aug 2015 04:07pm EDT 

Genomic Health Inc:Expects FY 2015 revenue of $289 to $302 million (formerly $292 to $305 million).Expects FY 2015 Net loss between $19 and $26 million (formerly $17 and $24 million), or basic net loss per share of between $0.59 and $0.81.FY 2015 revenue of $294 million and net income of $(23) million - Thomson Reuters I/B/E/S.  Full Article

Genomic Health Inc presents positive proof-of-concept data for bladder cancer liquid biopsy test
Tuesday, 16 Jun 2015 08:00am EDT 

Genomic Health Inc:Says positive results from a liquid biopsy proof-of-concept study demonstrating its ability to more conveniently detect disease recurrence with a level of accuracy comparable to cystoscopy, an invasive procedure for surveillance of early-stage bladder cancer.These results support Genomic Health's development of a urine test that may offer physicians and patients a non-invasive alternative for physicians to monitor patients' bladder cancer.Early-stage bladder cancer is estimated to recur in 10 to 15 percent of patients in the first year and in more than half of patients over time.Currently, bladder cancer surveillance is repeated at frequent intervals via a cystoscopy, a procedure that inserts an instrument equipped with a camera and light to look at the inside of the bladder.  Full Article

More From Around the Web

BRIEF-Genomic Health Q4 EPS $0.04

* Genomic health announces 2016 fourth quarter and year-end financial results, provides 2017 financial outlook